News - Oncology, MedImmune

Filter

Current filters:

OncologyMedImmune

Popular Filters

AstraZeneca showcases much awaited oncology pipeline at ASCO 2014

AstraZeneca showcases much awaited oncology pipeline at ASCO 2014

03-06-2014

Anglo-Swedish drug major AstraZeneca provided an update on the rapid development of its oncology pipeline…

AstraZenecaAZD9291MED14736MedImmuneOncologyPharmaceuticalResearchtremelimumab

MedImmune and Incyte to collaborate on immunotherapy

MedImmune and Incyte to collaborate on immunotherapy

14-05-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaBahija JallalIncyteL1LicensingMajorMedImmuneOncologyPharmaceuticalTumorTumorsUKUSA

Medimmune announces research deals with University of Cambridge and University of Texas

Medimmune announces research deals with University of Cambridge and University of Texas

18-03-2014

USA-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

MedImmuneOncologyPharmaceuticalResearchUKUSA

AstraZeneca in deal with Immunocore to develop novel cancer therapies

AstraZeneca in deal with Immunocore to develop novel cancer therapies

08-01-2014

UK privately-held biotech firm Immunocore has signed an oncology research collaboration and licensing…

AstraZenecaBiotechnologyImmunocoreLicensingMedImmuneOncologyResearch

AstraZeneca boosts oncology portfolio with up to $440 million acquisition

AstraZeneca boosts oncology portfolio with up to $440 million acquisition

15-10-2013

AstraZeneca revealed this morning that its biologics subsidiary MedImmune has acquired Spirogen, a privately-held…

ADC TherapeuticsAstraZenecaMedImmuneMergers & AcquisitionsOncologyPharmaceuticalSpirogen

AstraZeneca plans to move three cancer drug candidates into Ph III

16-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning (May 16) announced that it will be moving…

AstraZenecaBiotechnologyMedImmunemoxetumomab pasudotoxolaparibOncologyPharmaceuticalResearchselumetinib

AgonOx partners with AstraZeneca unit for development of OX40 agonists in cancer therapy

02-11-2011

USA-based AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics…

AgonOxAstraZenecaBiotechnologyLicensingMedImmuneOncologyPharmaceuticalResearch

AstraZeneca unit in-licenses Pfizer drug candidate tremelimumab

04-10-2011

Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) US biologics subsidiary MedImmune has in-licensed…

AstraZenecaLicensingMedImmuneOncologyPfizerPharmaceutical

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top